Actively Recruiting
Evaluating the Efficacy and Safety of MLC901 NeuroAiD II in Mild to Moderate Ischemic Stroke Patients A Randomized Controlled Study
Led by EVD Pharmacy and Medical Company Limited · Updated on 2026-10-20
80
Participants Needed
1
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate the efficacy and safety of MLC901 NeuroAiD II in patients who have experienced mild to moderate ischemic stroke. It is a randomized, controlled, open-label Phase 4 study comparing MLC901 combined with standard treatment versus standard treatment alone. The study includes 80 patients aged 18 to 80 years, enrolled 2 to 10 days after stroke onset, who are clinically stable and suitable for rehabilitation. Participants will be randomly assigned to one of two groups one receiving MLC901 400 mg capsules, 2 capsules three times daily alongside standard stroke treatment, and the other receiving only the standard treatment, both for 12 weeks. An optional follow-up visit at Week 24 may assess how lasting the effects of treatment are. The study carefully monitors safety throughout. During the study, participants will undergo various assessments including quality of life questionnaires EQ-5D-5L, EQ-VAS, treatment satisfaction surveys, stroke severity scales NIHSS, mRS, motor function tests Fugl-Meyer Assessment, muscle strength evaluations, and MRI scans to measure brain infarct volume. Safety is tracked by monitoring adverse events and hemorrhagic complications from baseline up to 12 weeks and at the optional Week 24 visit. The entire participation may last up to 24 weeks for those attending the follow-up.
CONDITIONS
Brief Title
NeuroAiD Patient-Reported Outcomes in Patients With Mild to Moderate Ischemic Stroke
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here